(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/091610 A1

(51) International Patent Classification[7]: A61K 31/4164, C07D 233/00, A61P 35/00, 11/06, 37/08

(21) International Application Number: PCT/US2004/011010

(22) International Filing Date: 9 April 2004 (09.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/462,090 10 April 2003 (10.04.2003) US

(71) Applicant *(for all designated States except US)*: **AVANIR PHARMACEUTICALS** [US/US]; 11388 Sorrento Valley Road, Suite 200, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SIRCAR, Jagadish, C.** [US/US]; 4832 Riding Ridge Road, San Diego, CA 92130 (US). **THOMAS, Richard, J.** [US/US]; 12627 Sarsaparilla St., San Diego, CA 92129 (US). **RICHARDS, Mark, L.** [US/US]; 8532B Via Mallorca, La Jolla, CA 92037 (US). **KHATUYA, Haripada** [IN/US]; 13624 Via Cima Bella, San Diego, CA 92129 (US).

(74) Agent: **ALTMAN, Daniel, E.**; 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**
— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS

(57) Abstract: The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.

WO 2004/091610 A1